A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797
Active Not Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) in participants with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: UCLA, Los Angeles, California +121 locations
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
NCT04550260
Active Not Recruiting
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Research Site, Atlanta, Georgia +133 locations
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04223856
Active Not Recruiting
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona +259 locations
Conditions: Urothelial Cancer
Register for Updates
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00392327
Active Not Recruiting
This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Chemotherapy drugs, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination... Read More
Gender:
ALL
Ages:
Between 3 years and 22 years
Trial Updated:
06/04/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +184 locations
Conditions: Anaplastic Medulloblastoma, Medulloblastoma
Register for Updates
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
NCT00981058
Completed
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: ImClone Investigational Site, Chandler, Arizona +181 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03661320
Active Not Recruiting
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Local Institution - 0022, Tucson, Arizona +171 locations
Conditions: Muscle-Invasive Bladder Cancer, Urinary Bladder Neoplasms
Register for Updates
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
NCT01302834
Active Not Recruiting
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not ye... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/23/2025
Locations: Providence Cancer Center, Anchorage, Alaska +184 locations
Conditions: Head and Neck Cancer, Precancerous Condition
Register for Updates
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555
Active Not Recruiting
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/22/2025
Locations: Research Site, Duarte, California +158 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241
Active Not Recruiting
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/21/2025
Locations: Research Site, Los Angeles, California +221 locations
Conditions: Urothelial Cancer
Register for Updates
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
NCT04774380
Completed
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/20/2025
Locations: Research Site, Panagyurishte, Not set +34 locations
Conditions: Extensive-stage Small Cell Lung Cancer
Register for Updates
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT05007106
Active Not Recruiting
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Alaska Womens Cancer Care ( Site 1016), Anchorage, Alaska +72 locations
Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Register for Updates
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248
Recruiting
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
05/12/2025
Locations: BCCA - Vancouver, Vancouver, British Columbia +3 locations
Conditions: Lymphoma, B-Cell
Register for Updates